SCHEMBL25848872

SCHEMBL25848872

CNS(=O)(=O)c1ccc(C(=O)OC)s1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.72
NPSR1 Q6W5P4 2/20 0.72
PPARG P37231 1/20 0.72
NCOA2 Q15596 1/20 0.72
NCOA1 Q15788 1/20 0.72
NCOA3 Q9Y6Q9 1/20 0.72
TSHR P16473 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
HPGD P15428 2/20 0.44
MAPK1 P28482 1/20 0.44
ATM Q13315 1/20 0.44
PARP1 P09874 1/20 0.38
HTT P42858 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
MAPT P10636 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7894260 0.86 LMNA (0.51) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL22638687 0.84 LMNA (0.51) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL14284027 0.82 NPSR1 (0.77) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL22652510 0.82 LMNA (0.47) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL2006698 0.81 NPSR1 (0.74) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL18090589 0.81 NPSR1 (0.74) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL22652251 0.79 NPSR1 (0.72) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL25848977 0.78 LMNA (0.70) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL24196385 0.77 LMNA (0.68) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL70027 0.77 NPSR1 (0.67) LMNANPSR1PPARGNCOA2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-07-13 US disclosed
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-07-13 US disclosed
CN-116075297-A KCNT1 inhibitors and methods of use 普拉西斯精密医药公司 2023-05-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE KCNT1, KCNT2, KCNQ2 LMNA 1423/4885NPSR1 2433/4885PPARG 4045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.